Sugi Predict

Sugi Predict / Compounds / SCHEMBL5553570

SCHEMBL5553570

SCHEMBL5553570

CCOc1ccc(Nc2nc(Nc3ccccc3C)nc(NC(CC)C3CCCN3)n2)cc1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ EGFR P00533 1/20 0.37
▸ SOS1 Q07889 2/20 0.37
▸ ALK Q9UM73 4/20 0.35
▸ P2RX3 P56373 3/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ CCNA2 P20248 3/20 0.33
▸ CDK2 P24941 3/20 0.33
▸ CCNK O75909 2/20 0.33
▸ CDK9 P50750 2/20 0.33
▸ RECQL P46063 1/20 0.33
▸ CCND3 P30281 1/20 0.33
▸ CDK6 Q00534 1/20 0.33
▸ JAK2 O60674 1/20 0.33
▸ PTK2 Q05397 1/20 0.33
▸ RORC P51449 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5553372 0.85 BCL6 (0.43) MAPTMEN1LMNAKMT2ASOS1
SCHEMBL4838361 0.83 MAPT (0.38) MAPTMEN1LMNAKMT2AEGFR
SCHEMBL5445013 0.80 MAPT (0.45) MAPTMEN1LMNAKMT2ASOS1
SCHEMBL5031382 0.80 BCL6 (0.40) MEN1KMT2AEGFRSOS1RAB9A
SCHEMBL5550350 0.79 BCL6 (0.42) MAPTMEN1LMNAKMT2ASOS1
SCHEMBL5032200 0.78 BCL6 (0.50) MAPTMEN1LMNAKMT2ANPC1
SCHEMBL5035753 0.77 GALR1 (0.37) MAPTMEN1LMNAKMT2ASOS1
SCHEMBL5032213 0.76 GALR1 (0.43) MAPTMEN1LMNAKMT2ASOS1
SCHEMBL5554475 0.76 MAPT (0.46) MAPTMEN1LMNAKMT2AEGFR
SCHEMBL5549818 0.76 CTSS (0.39) MAPTMEN1KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7238692-B2 Medical devices employing triazine compounds and compositions thereof REDDY US THERAPEUTICS, INC. (US) 2007-07-03 — — US claimed
US-7169785-B2 Methods and compositions of novel triazine compounds REDDY US THERAPEUTICS, INC. (US) 2007-01-30 — — US claimed
US-20050124619-A1 Medical devices employing triazine compounds and compositions thereof DR. REDDY'S LABORATORIES LTD. (IN) 2005-06-09 — — US claimed
WO-2004026844-A9 METHODS AND COMPOSITIONS OF NOVEL TRIAZINE COMPOUNDS REDDY US THERAPEUTICS INC (US) 2004-11-11 — — WO claimed
US-20040209882-A1 Methods and compositions of novel triazine compounds DR. REDDY'S LABORATORIES LTD. (IN) 2004-10-21 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040209882-A1 Methods and compositions of novel triazine compounds AREG, TGFB1, PTGIS MAPT 3539/4885MEN1 4761/4885LMNA 2238/4885
US-20050124619-A1 Medical devices employing triazine compounds and compositions thereof PTGIS, AREG, TGFB1 MAPT 3475/4885MEN1 4510/4885LMNA 3439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.